VERONA PHARMA PLC - AMERICAN DEPOSITARY SHARES

Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

21 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD

20 Dec 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD

19 Dec 2022 15:01:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update

09 Nov 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces November 2022 Investor Conference Participation

02 Nov 2022 02:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update

26 Oct 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance

17 Oct 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD

14 Oct 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

29 Aug 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma strengthens commercialization leadership team

24 Aug 2022 01:00:00 By Nasdaq GlobeNewswire

Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China

19 Aug 2022 01:46:07 By Nasdaq GlobeNewswire

Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs

15 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering

10 Aug 2022 19:22:20 By Nasdaq GlobeNewswire

Verona Pharma plc Announces Proposed Underwritten Public Offering

09 Aug 2022 15:16:44 By Nasdaq GlobeNewswire

Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update

09 Aug 2022 02:01:03 By Nasdaq GlobeNewswire

Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD

09 Aug 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD

08 Aug 2022 15:30:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update

29 Jul 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

09 Jun 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Host KOL Event on June 16, 2022

06 Jun 2022 01:00:00 By Nasdaq GlobeNewswire